SPEEDCAST
Speedcast International Limited (ASX: SDA), the world’s most trusted provider of highly reliable, fully managed, remote communication and IT solutions, today announced its Chief Executive Officer Pierre-Jean Beylier has been selected as one of the winners of the Finance Monthly CEO Awards 2017 . This accolade recognises Beylier’s outstanding financial achievements at Speedcast over the past 12 months.
Beylier has been with Speedcast since December 2000 and was appointed CEO in July 2004. Under his leadership, Speedcast has become the leader in the global satellite services industry, servicing customers in over 100 countries with operations on land, at sea and in the air. He spearheaded the group’s external growth strategy, acquiring 14 companies over the last five years, successfully building market share, developing a unique product and services portfolio, and leading its successful IPO on the Australian stock exchange in August 2014.
“I am honored to receive the Finance Monthly’s CEO Award for 2017,” said Beylier. “I would like to thank Speedcast’s dedicated employees for their passion and hard work. We would not be able to achieve what we did today without the support and commitment of all our employees and customers.”
Award nominations are open worldwide to all C-level executives from private or public companies. Researchers at Finance Monthly determine the suitability of the CEO/C-Level Executive based on his or her achievements. Achievements are defined and scored upon the following criteria; growth in revenues and/or profits, turnaround transformation, exceeding expectations in difficult markets, growth within new markets, leading market share, successful M&A integration, delivering and producing new products and services. More information about the Finance Monthly CEO Awards can be found at https://ceoawards.finance-monthly.com/ .
About Speedcast International Limited
Speedcast International Ltd (ASX: SDA) is the world’s most trusted provider of highly reliable, fully managed, end-to-end remote communication and IT solutions. The company utilizes an extensive worldwide footprint of local support, infrastructure and coverage to design, integrate, secure and optimize networks tailored to customer needs. With differentiated technology, an intense customer focus and a strong safety culture, Speedcast serves more than 2,000 customers in over 140 countries via 39 teleports, including offshore rigs and cruise ships, 10,000+ maritime vessels and 4,500+ terrestrial sites. Speedcast supports mission-critical applications in industries such as maritime, oil and gas, enterprise, media, cruise and government. Learn more at www.Speedcast.com .
Social Media: Twitter | LinkedIn | Facebook
Speedcast® is a trademark and registered trademark of Speedcast International Limited. All other brand names, product names, or trademarks belong to their respective owners.
© 2017 Speedcast International Limited. All rights reserved.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170703005623/en/
Contact:
Speedcast International Ltd
Toni Lee Rudnicki,
+1-832-668-2634
Vice
President, Global Marketing
ToniLee.Rudnicki@Speedcast.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom